Royalty Pharma is a buyer of biopharmaceutical royalties. The royalties in Co.'s marketed portfolio related to approved products include: cystic fibrosis franchise, which consists of Co.'s right to receive royalty payments on the sale of various products for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor); and Tysabri, which is a monoclonal antibody for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. More details about Royalty Pharma at:
http://www.royaltypharma.com.
ETFs holding RPRX »
Should Royalty Pharma shares be counted among the
Top 10 Cheapest Stocks Right Now? To start, we see that the recent trading price for RPRX stock is $27.89 (as of 4/18/2024). The most recent quarter's (MRQ) earnings result, annualized, was $4.6/share. Looking at the sum total of quarterly earnings across the trailing twelve month (TTM) period, Royalty Pharma produced $4.38/share. And taking the median quarterly result across the TTM period, and annualizing it, results in $3.96/share. Comparing these various earnings metrics against the stock price, we end up with a PE ratio of 7.0 for the TTM Median method, 6.1 for price to earnings using MRQ annualized, and 6.4 for current price/TTM earnings. Based on RPRX's history, that recent TTM PE is low relative to the historical average, with the recent PE 69.4% lower than the average (TTM method) of 20.9.